MedTrace Logo

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

NCT01524302 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-04-12

Study results available
· View outcomes & findings →

Summary

This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.

Conditions

  • Pneumonia, Bacterial
  • Community-acquired

Interventions

DRUG

Ceftaroline

600 mg Q12h

DRUG

Levofloxacin

750 mg QD

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Gary E. Stein, Pharm.D.

    lead OTHER

Principal Investigators

  • Gary E Stein, Pharm.D. · Michigan State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-05-31
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01524302 on ClinicalTrials.gov